Completed PHASE2/PHASE3 INTERVENTIONAL 2-arm NCT01691768

Implementation Effectiveness and Safety of Tenofovir Gel Provision Through Family Planning Services

Open-Label Randomized Controlled Trial to Assess the Implementation Effectiveness and Safety of 1% Tenofovir Gel Provision Through Family Planning Services in KwaZulu-Natal, South Africa

Sponsor: CONRAD

Conditions HIV

Interventions 1% tenofovir gel

Updated 7 times since 2017 Last updated: Nov 7, 2019 Started: Oct 31, 2012 Primary completion: Apr 30, 2015 Completion: Dec 31, 2015

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT01691768, this PHASE2/PHASE3 trial focuses on HIV and remains completed. Sponsored by CONRAD, it has been updated 7 times since 2012, reflecting limited change activity. This study is part of the global effort to build evidence for infectious disease interventions.

Status Flow

Change History

7 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2/PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2/PHASE3

Phase: PHASE2_PHASE3 → PHASE2/PHASE3
Dec 2021 — Jul 2024 [monthly]

Completed PHASE2_PHASE3
Jan 2021 — Dec 2021 [monthly]

Completed PHASE2_PHASE3
Dec 2019 — Jan 2021 [monthly]

Completed PHASE2_PHASE3

▶ Show 2 earlier versions

Jun 2018 — Dec 2019 [monthly]

Completed PHASE2_PHASE3
Jan 2017 — Jun 2018 [monthly]

Completed PHASE2_PHASE3

First recorded

Oct 2012

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

CONRAD
Centre for the AIDS Programme of Research in South Africa
FHI 360
Gilead Sciences
Institute for Healthcare Improvement

Data source: Centre for the AIDS Programme of Research in South Africa

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Durban, South Africa
• Pietermaritzburg, South Africa